202 related articles for article (PubMed ID: 38006616)
21. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
22. Short interfering RNA directed against the E2F-1 gene suppressing gastric cancer progression in vitro.
Xie Y; Yin Y; Li L; Ma Y; Xiao Q
Oncol Rep; 2009 May; 21(5):1345-53. PubMed ID: 19360313
[TBL] [Abstract][Full Text] [Related]
23. Sustained delivery of siRNA/PEI complex from in situ forming hydrogels potently inhibits the proliferation of gastric cancer.
Peng H; Yang H; Song L; Zhou Z; Sun J; Du Y; Lu K; Li T; Yin A; Xu J; Wei S
J Exp Clin Cancer Res; 2016 Mar; 35():57. PubMed ID: 27029190
[TBL] [Abstract][Full Text] [Related]
24. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
25. Regression of Gastric Cancer by Systemic Injection of RNA Nanoparticles Carrying both Ligand and siRNA.
Cui D; Zhang C; Liu B; Shu Y; Du T; Shu D; Wang K; Dai F; Liu Y; Li C; Pan F; Yang Y; Ni J; Li H; Brand-Saberi B; Guo P
Sci Rep; 2015 Jul; 5():10726. PubMed ID: 26137913
[TBL] [Abstract][Full Text] [Related]
26. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
27. A review on RNAi therapy for NSCLC: Opportunities and challenges.
Kumar V; Yadavilli S; Kannan R
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Mar; 13(2):e1677. PubMed ID: 33174364
[TBL] [Abstract][Full Text] [Related]
28. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
[TBL] [Abstract][Full Text] [Related]
29. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
[TBL] [Abstract][Full Text] [Related]
31. Recent developments in nanoparticle-based siRNA delivery for cancer therapy.
Lee JM; Yoon TJ; Cho YS
Biomed Res Int; 2013; 2013():782041. PubMed ID: 23844368
[TBL] [Abstract][Full Text] [Related]
32. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.
Xie FY; Woodle MC; Lu PY
Drug Discov Today; 2006 Jan; 11(1-2):67-73. PubMed ID: 16478693
[TBL] [Abstract][Full Text] [Related]
33. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
34. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
35. Advances in siRNA delivery in cancer therapy.
Singh A; Trivedi P; Jain NK
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
37. Small-interfering RNA (siRNA)-based functional micro- and nanostructures for efficient and selective gene silencing.
Lee SH; Chung BH; Park TG; Nam YS; Mok H
Acc Chem Res; 2012 Jul; 45(7):1014-25. PubMed ID: 22413937
[TBL] [Abstract][Full Text] [Related]
38. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges.
Won Lee J; Kyu Shim M; Kim H; Jang H; Lee Y; Hwa Kim S
Adv Drug Deliv Rev; 2023 Oct; 201():115073. PubMed ID: 37657644
[TBL] [Abstract][Full Text] [Related]
39. Bioengineered nanoparticles for siRNA delivery.
Kozielski KL; Tzeng SY; Green JJ
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):449-68. PubMed ID: 23821336
[TBL] [Abstract][Full Text] [Related]
40. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy.
Mirzaei S; Gholami MH; Hashemi F; Zabolian A; Hushmandi K; Rahmanian V; Entezari M; Girish YR; Sharath Kumar KS; Aref AR; Makvandi P; Ashrafizadeh M; Zarrabi A; Khan H
Life Sci; 2021 Jul; 277():119430. PubMed ID: 33789144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
